Clinically relevant kinetics and interactions Flashcards
Percentage of Caucasians who are slow TCA metabolisers
7-9%
Reason some Caucasians are slow TCA metabolisers
CYP2D6 polymorphism
Timing to take TCA plasma levels to assess therapeutic dosing
After 5-7 days when steady state is reached
8-12 hours after last dose
Therapeutic window for nortriptyline - due to lack of effect at higher doses, not due to side effects
50-150ng/ml
TCAs which decrease the metabolism of morphine and can lead to opioid toxicity
Amitriptyline
Clomipramine
Medications which inhibit TCA metabolism and can increase plasma TCA levels
Quinidine Cimetidine Fluoxetine Paroxetine Phenothiazines e.g. chlorpromazine Disulfiram Methylphenidate
Medications which induce TCA metabolism and can reduce TCA levels
Phenytoin
Carbamazepine
Oral contraceptives
Barbiturates
Interaction between TCAs and phenothiazines e.g. chlorpromazine
Mutual inhibition of metabolism - both phenothiazine and TCA levels increase
Effect of smoking on TCA metabolism
Induces metabolism, TCA levels increase
Effect of TCAs on warfarin levels
Increase warfarin levels
Effect of TCAs on clonidine levels
Reduce clonidine levels, can cause a hypertensive crisis
Interactions between TCAs and MAOIs
Synergistic serotonin enhancement especially with clomipramine - higher risk of serotonin syndrome
TCAs reduce tyramine entry via monoamine reuptake channels - lower risk of cheese reaction
Interaction between TCAs and l-dopa
TCAs reduce absorption of l-dopa and lower efficacy
Mechanism by which amitriptyline and clomipramine decrease the metabolism of morphine
UDP glucuronyl transferase interaction
SSRI with the greatest linearity of kinetics and most predictable side effects
Fluvoxamine
SSRI with the greatest non-linearity of kinetics and most unpredictable side effects
Paroxetine
Least protein bound SSRI
Escitalopram
SSRIs without active metabolites
Fluvoxamine
Paroxetine
SSRIs which can inhibit their own clearance
Fluoxetine
Paroxetine
Most selective SSRIs
Citalopram
Escitalopram
Most potent SSRI
Paroxetine
SSRI which has significant anticholinergic effects at higher doses
Paroxetine
SSRI which impairs the clearance of diazepam and should not be co-prescribed
Fluvoxamine
Interaction between SSRIs (not sertraline and citalopram) and TCAs
Increases levels of TCAs and can cause toxicity or can be associated with therapeutic benefit
Interaction between fluvoxamine and theophylline
Fluvoxamine reduces the clearance of theophylline through CYP1A2 inhibition
If co-administered theophylline dose should be one third normal dose
Interaction between fluvoxamine and warfarin
Warfarin plasma levels nearly double - dose requires adjustment